Videos

The hospitalist at Memorial Sloan Kettering Cancer Center spoke about the design of a study which evaluated the use of 177Lu-DOTATATE in patients with well-differentiated, high-grade neuroendocrine tumors.

Kelley Lauren Coffman, MD, on the Design of a Study of 177Lu-DOTATATE in Well-Differentiated, High-Grade NETs

The expert in hematology/oncology spoke about the study which evaluated the use of peptide receptor radionuclide therapy in patients with well-differentiated neuroendocrine tumors.

Satya Das, MD, MSCI, on the Design of a Study of PRRT in Patients With Well-Differentiated NETs

SWOG S1406 evaluated the use of irinotecan and cetuximab (Erbitux) with or without vemurafenib (Zelboraf) in patients with BRAF V600E-mutated metastatic colorectal cancer who had been previously treated with 1 or 2 regimens.

Scott Kopetz, MD, PhD, on the Results of the SWOG S1406 Trial

Based on findings from the trial of ciltacabtagene autoleucel, further investigation of the therapy in other populations of patients with multiple myeloma is already underway.

Deepu Madduri, MD, on the Implications of the Phase 1b/2 CARTITUDE-1 Trial Results

IDH1/2 mutations have been detected in nearly 20% of patients with acute myeloid leukemia.

Dan Pollyea, MD, MS, on the Discovery and Incidence of IDH1 and IDH2 mutations in Patients With AML

Merryman provided background for the study design investigating patients with relapsed or refractory diffuse large B-cell lymphoma.

Reid Merryman, MD, Discusses Autologous Stem Cell Transplantation for Patients with DLBCL

A recent study sought to evaluate the 21-gene Oncotype Dx Recurrence Score in nonmetastatic HR-positive, HER2-negative breast cancer.

Kevin Kalinsky, MD, MS, on the Aim of the Phase 3 RxPONDER Trial in Breast Cancer Subtype

CancerNetwork spoke with Wade T. Iams, MD, about treatment options available and being evaluated in small cell lung cancer.

Assessing the Small Cell Lung Cancer Treatment Landscape

The goal of the CARTITUDE-1 study was to evaluate the use of ciltacabtagene autoleucel (cilta-cel; JNJ-68284528) chimeric antigen receptor T-cell therapy in heavily pretreated patients with relapsed or refractory multiple myeloma.

Deepu Madduri, MD, on the Design of the Phase 1b/2 CARTITUDE-1 Trial

An industry leader in psychosocial oncology detailed the importance of patient-reported outcomes to the field as a whole and emphasized a number of key details to remember when examining these end points.

Expert Interviews